Early cervical XXXX .

@entity1 @entity66 @entity5 @entity900 @entity3846 @entity3 @entity850
Early cervical @entity5 includes a @entity66 , from clinically undetectable microinvasive @entity5 that replace the entire cervix. Further subgrouping of this category is therefore necessary to define the optimal treatment approach for individual cases. The International Federation of Gynecology and Obstetrics (FIGO) staging system stratifies stage I @entity5 into two broad categories, stage IA (microinvasive) and stage IB (gross @entity5 ). Management of @entity1 with stage IA disease is controversial. In the United States, @entity1 with stromal invasion of less than 3 mm and no lymphvascular involvement are usually treated conservatively with simple hysterectomy. In selected @entity1 who desire fertility, cone biopsy with negative surgical margins is also considered. @entity1 with invasion of more than 3 mm or lymphvascular space involvement are at risk for pelvic lymph node @entity3 and are most often treated with radical hysterectomy and pelvic lymphadenectomy. Stage @entity3846 cervical @entity5 is managed by either radical surgery or radiotherapy with equivalent recurrence and survival rates. In @entity1 with @entity5 less than 4 cm in diameter, the decision between radical surgery and radiotherapy is guided by @entity1 ' overall health and treatment preferences. For younger @entity1 , radical surgery is preferred because ovarian function can be preserved and vaginal @entity850 secondary to radiation can be avoided. Radiation therapy is preferred for @entity1 who may not tolerate radical surgery. We always prefer primary radiation therapy for @entity1 with @entity5 larger than 4 cm in diameter. Recent data convincingly demonstrate that the addition of @entity900 -based chemotherapy significantly improves overall survival rates in cervical @entity5 @entity1 who undergo radiation therapy.
